Form D · Other
CHARM Therapeutics Inc.
London, X0 · CIK 0001889676
Offering snapshot reported Sep 3, 2025 · SEC filing
- Reported sold
- $17.3M Offering amount: $80.1M
- Investors reported
- 20 Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Aug 19, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 3, 2025 | Initial | $17,290,119 | No comparison | 20 | SEC filing |
| Apr 14, 2023 | Initial | $20,045,588 | No comparison | 2 | SEC filing |
| Jun 24, 2022 | Initial | $36,999,990 | No comparison | 18 | SEC filing |
| Oct 22, 2021 | Initial | $12,645,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-556495
Total Offering Amount includes the conversion of $5,183,401.71 in Convertible Notes.
Source: Form D, filed Sep 3, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lakshyaditya Singh Aithani | Director, Executive |
| Kim Blackwell | Director |
| Gary Glick | Director, Executive, Promoter |
| Rishi Gupta | Director |
| Mahesh Kudari | Director |
| Muzammil Mansuri | Director |
| Matthew Mc Aviney | Director |
| Briggs Morrison | Director |
| Nihal Sinha | Director |
Issuer details
Industry: Other (See others in industry)
Address:
7 Pancras Square
London, X0, N1C 4AG
London, X0, N1C 4AG